Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.11 Million USD | -54.09% |
| 2022 | 6.77 Million USD | -24.84% |
| 2021 | 9.01 Million USD | 78.23% |
| 2020 | 5.05 Million USD | -21.59% |
| 2019 | 6.45 Million USD | -53.73% |
| 2018 | 13.94 Million USD | -9.08% |
| 2017 | 15.33 Million USD | 27.74% |
| 2016 | 12 Million USD | -7.33% |
| 2015 | 12.95 Million USD | 61.18% |
| 2014 | 8.03 Million USD | 169.46% |
| 2013 | 2.98 Million USD | -28.93% |
| 2012 | 4.19 Million USD | -27.29% |
| 2011 | 5.77 Million USD | 72.51% |
| 2010 | 3.34 Million USD | 133.75% |
| 2009 | 1.43 Million USD | 180.59% |
| 2008 | 510.19 Thousand USD | 981.81% |
| 2007 | 47.16 Thousand USD | 38.21% |
| 2006 | 34.12 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 229 Thousand USD | 48.54% |
| 2023 Q2 | 333 Thousand USD | -75.9% |
| 2023 Q1 | 1.38 Million USD | 7.88% |
| 2023 Q3 | 641 Thousand USD | 92.49% |
| 2023 Q4 | 583 Thousand USD | -9.05% |
| 2023 FY | 2.56 Million USD | -62.13% |
| 2022 Q1 | 2.02 Million USD | -20.01% |
| 2022 FY | 6.77 Million USD | -24.84% |
| 2022 Q4 | 1.28 Million USD | -12.14% |
| 2022 Q3 | 1.45 Million USD | -27.61% |
| 2022 Q2 | 2.01 Million USD | -0.44% |
| 2021 Q2 | 3.43 Million USD | 204.61% |
| 2021 Q3 | 1.91 Million USD | -44.23% |
| 2021 Q4 | 2.52 Million USD | 31.86% |
| 2021 FY | 9.01 Million USD | 78.23% |
| 2021 Q1 | 1.12 Million USD | -21.98% |
| 2020 FY | 5.05 Million USD | -21.59% |
| 2020 Q2 | 1.34 Million USD | 0.3% |
| 2020 Q1 | 1.34 Million USD | 0.83% |
| 2020 Q3 | 925 Thousand USD | -31.23% |
| 2020 Q4 | 1.44 Million USD | 56.43% |
| 2019 Q1 | 1.99 Million USD | -22.91% |
| 2019 Q3 | 1.12 Million USD | -43.43% |
| 2019 Q4 | 1.33 Million USD | 17.91% |
| 2019 FY | 6.45 Million USD | -53.73% |
| 2019 Q2 | 1.99 Million USD | -0.25% |
| 2018 Q2 | 4.46 Million USD | -0.36% |
| 2018 Q4 | 2.59 Million USD | 8.13% |
| 2018 FY | 13.94 Million USD | -9.08% |
| 2018 Q1 | 4.48 Million USD | -13.72% |
| 2018 Q3 | 2.39 Million USD | -46.33% |
| 2017 Q3 | 3.85 Million USD | 16.41% |
| 2017 FY | 15.33 Million USD | 27.74% |
| 2017 Q4 | 5.19 Million USD | 34.92% |
| 2017 Q2 | 3.3 Million USD | 11.11% |
| 2017 Q1 | 2.97 Million USD | 16.92% |
| 2016 Q2 | 3.27 Million USD | 29.56% |
| 2016 Q3 | 3.65 Million USD | 11.76% |
| 2016 Q1 | 2.52 Million USD | -17.2% |
| 2016 FY | 12 Million USD | -7.33% |
| 2016 Q4 | 2.54 Million USD | -30.39% |
| 2015 Q1 | 4.35 Million USD | 32.33% |
| 2015 Q3 | 2.84 Million USD | 5.21% |
| 2015 Q2 | 2.7 Million USD | -37.9% |
| 2015 FY | 12.95 Million USD | 61.18% |
| 2015 Q4 | 3.05 Million USD | 7.28% |
| 2014 Q4 | 3.29 Million USD | 44.13% |
| 2014 FY | 8.03 Million USD | 169.46% |
| 2014 Q3 | 2.28 Million USD | 47.64% |
| 2014 Q2 | 1.54 Million USD | 68.31% |
| 2014 Q1 | 918.65 Thousand USD | -15.3% |
| 2013 FY | 2.98 Million USD | -28.93% |
| 2013 Q1 | 408.91 Thousand USD | -72.99% |
| 2013 Q2 | 688.74 Thousand USD | 68.43% |
| 2013 Q3 | 800.75 Thousand USD | 16.26% |
| 2013 Q4 | 1.08 Million USD | 35.45% |
| 2012 Q4 | 1.51 Million USD | 111.42% |
| 2012 FY | 4.19 Million USD | -27.29% |
| 2012 Q2 | 1.07 Million USD | 19.97% |
| 2012 Q1 | 894.15 Thousand USD | -29.02% |
| 2012 Q3 | 716.15 Thousand USD | -33.24% |
| 2011 FY | 5.77 Million USD | 72.51% |
| 2011 Q3 | 2.22 Million USD | 72.53% |
| 2011 Q4 | 1.25 Million USD | -43.47% |
| 2011 Q1 | 992.62 Thousand USD | 16.01% |
| 2011 Q2 | 1.29 Million USD | 30.12% |
| 2010 FY | 3.34 Million USD | 133.75% |
| 2010 Q2 | 1.18 Million USD | 123.3% |
| 2010 Q4 | 855.63 Thousand USD | 9.48% |
| 2010 Q3 | 781.52 Thousand USD | -33.79% |
| 2010 Q1 | 528.6 Thousand USD | 82.61% |
| 2009 FY | 1.43 Million USD | 180.59% |
| 2009 Q4 | 289.46 Thousand USD | -54.9% |
| 2009 Q3 | 641.87 Thousand USD | 103.08% |
| 2009 Q2 | 316.06 Thousand USD | 71.66% |
| 2009 Q1 | 184.12 Thousand USD | -14.9% |
| 2008 Q1 | 15.57 Thousand USD | -3.92% |
| 2008 Q2 | 117.63 Thousand USD | 655.49% |
| 2008 FY | 510.19 Thousand USD | 981.81% |
| 2008 Q3 | 176.2 Thousand USD | 49.8% |
| 2008 Q4 | 216.35 Thousand USD | 22.78% |
| 2007 Q2 | 13.42 Thousand USD | 42.22% |
| 2007 Q3 | 9100.00 USD | -32.19% |
| 2007 Q1 | 9436.00 USD | 0.0% |
| 2007 Q4 | 16.2 Thousand USD | 78.08% |
| 2007 FY | 47.16 Thousand USD | 38.21% |
| 2006 FY | 34.12 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -132.958% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 38.299% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 89.473% |
| Nascent Biotech, Inc. | 2.22 Million USD | -39.514% |
| Rebus Holdings, Inc. | 664 Thousand USD | -368.524% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 91.65% |
| Qrons Inc. | 643.67 Thousand USD | -383.317% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -698.581% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.584% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -648.774% |
| Skye Bioscience, Inc. | 13.54 Million USD | 77.036% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.415% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 36.741% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1088.648% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.366% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -6.679% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -107.138% |
| Mesoblast Limited | 5.9 Million USD | 47.289% |
| Marizyme, Inc. | 19.23 Million USD | 83.83% |
| Genus plc | 147.7 Million USD | 97.894% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 64.564% |
| Pharming Group N.V. | 225.49 Million USD | 98.62% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -51.852% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -131.897% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 62.693% |
| ContraFect Corporation | 56.88 Million USD | 94.531% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 29.435% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -110.38% |
| IMV Inc. | 37.7 Million USD | 91.75% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -11.491% |
| MultiCell Technologies, Inc. | 567.42 USD | -548171.122% |
| ONE Bio Corp. | 6.44 Million USD | 51.722% |
| Accustem Sciences Inc. | 3.74 Million USD | 16.961% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.38% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -484.816% |
| Q BioMed Inc. | 3.43 Million USD | 9.475% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 87.413% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -18.401% |
| Biomind Labs Inc. | 994.18 Thousand USD | -212.921% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.868% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -76.794% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 53.692% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -66.866% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 12544.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 80.569% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -69.528% |
| GB Sciences, Inc. | 1.42 Million USD | -119.006% |
| Alpha Cognition Inc. | 9.7 Million USD | 67.946% |
| HST Global, Inc. | 140.9 Thousand USD | -2107.839% |
| CSL Limited | 3.44 Billion USD | 99.91% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -176.555% |
| Halberd Corporation | 74.84 Thousand USD | -4056.757% |
| Enzolytics Inc. | 2.17 Million USD | -42.739% |
| Agentix Corp. | 1.37 Million USD | -126.79% |
| Resverlogix Corp. | 12.71 Million USD | 75.527% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 14.784% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.797% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -197.989% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -29.359% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -96.979% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 8.634% |
| AVAX Technologies, Inc. | 7.31 Million USD | 57.443% |
| Zenith Capital Corp. | 8.94 Million USD | 65.213% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.623% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -17757.758% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -26.705% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1713.899% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -61.955% |
| Kadimastem Ltd | 2.41 Million USD | -29.081% |
| Helix BioMedix, Inc. | 1.97 Million USD | -57.756% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 71.372% |
| BioStem Technologies, Inc. | 22.97 Million USD | 86.459% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1614.191% |
| LadRx Corporation | 3.81 Million USD | 18.385% |
| Cell Source, Inc. | 4.32 Million USD | 28.075% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -236.867% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -236.867% |
| NovAccess Global Inc. | 2.46 Million USD | -26.117% |
| Affymax, Inc. | 39.38 Million USD | 92.101% |
| Itoco Inc. | 919.14 Thousand USD | -238.467% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 26.6% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -178.016% |
| Mobile Lads Corp. | 554.54 Thousand USD | -460.999% |
| CytoDyn Inc. | 18.05 Million USD | 82.772% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -12260.443% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1313.59% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -119.117% |
| SYBLEU INC | 160.87 Thousand USD | -1833.788% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -71.28% |
| International Stem Cell Corporation | 5.27 Million USD | 40.979% |
| Bioxytran, Inc. | 3.82 Million USD | 18.563% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5809.73% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -15192.73% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 91.422% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -92.274% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -322.785% |
| Neutra Corp. | 243.82 Thousand USD | -1175.936% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 82.179% |
| PureTech Health plc | 144.59 Million USD | 97.849% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 84.817% |
| IXICO plc | 4.7 Million USD | 33.907% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 64.636% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.358% |
| CSL Limited | 3.89 Billion USD | 99.92% |
| Cellectis S.A. | 97.32 Million USD | 96.803% |